A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma
Authors
Fugen Li (ORCID: https://orcid.org/0000-0002-1491-7667)
A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma
Fugen Li, Yue-Rong Shuang, Zegeng Chen, Zhigang Peng et al.
Citations
1 citations
Journal
Journal of Hematology & Oncology
Topics
Lymphoma Diagnosis and Treatment
Field-Weighted Citation Impact (FWCI)
1.47
article
A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma
Hebei Medical University (CN), Beijing Tongren Hospital (CN), Fujian Medical University (CN), Union Hospital (HK), Nanchang University (CN), Sun Yat-sen University (CN), Guangxi Medical University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Jiangxi Provincial Cancer Hospital (CN), Fourth Hospital of Hebei Medical University (CN), Hunan Cancer Hospital (CN), Sichuan Cancer Hospital (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), First Affiliated Hospital of GuangXi Medical University (CN), Henan Cancer Hospital (CN), Sun Yat-sen University Cancer Center (CN), First Affiliated Hospital of Zhengzhou University (CN), Union Hospital (CN), First Affiliated Hospital of Nanchang University (CN), Huazhong University of Science and Technology (CN), China Medical University (CN)
Funders
National Natural Science Foundation of China, Sun Yat-sen University, Sun Yat-sen University Cancer Center